Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
X4 Pharmaceuticals Inc (XFOR)
NASDAQ:XFOR
X4 Pharmaceuticals (XFOR) Stock Price & Analysis
794 Followers
XFOR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.57 - $2.58
Previous Close$0.96
Volume1.99M
Average Volume (3M)3.41M
Market Cap
$161.17M
Enterprise Value$138.58M
Total Cash (Recent Filing)$80.87M
Total Debt (Recent Filing)$58.27M
Price to Earnings (P/E)-1.4
Beta1.63
Next Earnings
Aug 01, 2024EPS Estimate
<$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding167,937,781
10 Day Avg. Volume3,105,840
30 Day Avg. Volume3,411,312
Standard Deviation0.23
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-10.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue949.15
Enterprise Value/Gross Profit710.65
Enterprise Value/Ebitda-2.60
Forecast
1Y Price Target
$4.33Price Target Upside366.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
X4 Pharmaceuticals News
Ownership Overview
10.73% Insiders
7.00% Mutual Funds
46.06% Other Institutional Investors
36.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
XFOR FAQ
What was X4 Pharmaceuticals Inc’s price range in the past 12 months?
X4 Pharmaceuticals Inc lowest stock price was $0.57 and its highest was $2.58 in the past 12 months.
What is X4 Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is X4 Pharmaceuticals Inc’s upcoming earnings report date?
X4 Pharmaceuticals Inc’s upcoming earnings report date is Aug 01, 2024 which is in 75 days.
How were X4 Pharmaceuticals Inc’s earnings last quarter?
X4 Pharmaceuticals Inc released its earnings results on May 07, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.106.
Is X4 Pharmaceuticals Inc overvalued?
According to Wall Street analysts X4 Pharmaceuticals Inc’s price is currently Undervalued.
Does X4 Pharmaceuticals Inc pay dividends?
X4 Pharmaceuticals Inc does not currently pay dividends.
What is X4 Pharmaceuticals Inc’s EPS estimate?
X4 Pharmaceuticals Inc’s EPS estimate is <$0.01.
How many shares outstanding does X4 Pharmaceuticals Inc have?
X4 Pharmaceuticals Inc has 167,937,770 shares outstanding.
What happened to X4 Pharmaceuticals Inc’s price movement after its last earnings report?
X4 Pharmaceuticals Inc reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -9.167%.
Which hedge fund is a major shareholder of X4 Pharmaceuticals Inc?
Among the largest hedge funds holding X4 Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds X4 Pharmaceuticals Inc’s shares valued at 3M.
---
X4 Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (366.39% Upside)
$4.33 (366.39% Upside)
Blogger Sentiment
Bullish
XFOR Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 269.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 0.1%
Last 30 Days ▼ 0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.51%
12-Months-Change
Fundamentals
Return on Equity
-489.12%
Trailing 12-Months
Asset Growth
-9.83%
Trailing 12-Months
Company Description
X4 Pharmaceuticals Inc
X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.
---
XFOR Earnings Call
Q1 2024
0:00 / 0:00
---
XFOR Stock 12 Month Forecast
Average Price Target
$4.33
▲(366.39% Upside)
Technical Analysis
ADMA Biologics
―
Apellis Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Assembly Biosciences
―
Best Analysts Covering XFOR
1 Year
1 Year Success Rate
6/15 ratings generated profit
1 Year Average Return
-12.49%
reiterated a buy rating 5 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -12.49% per trade.
---